Transplantation in the alcoholic patient

Kymberly D S Watt, Timothy M McCashland

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Alcoholic liver disease (ALD) is the second leading indication for transplantation in the United States. Most transplant programs in the United States require a minimum of 6 month's abstinence before transplantation is performed. Most studies have shown a recidivism rate of between 20 and 30% by 2 years after orthotopic liver transplantation (OLT). Higher rates of recidivism are reported if pre-OLT abstinence was < 6 months. The impact of recidivism on patient and graft survival is not clear because most reports include patients who consume alcohol in small amounts or infrequently. Equal post-OLT survival for ALD patients and non-ALD patients has been demonstrated, and ALD patients are not thought to suffer greater morbidity post transplant than non-ALD patients. Careful pretransplant assessment for concomitant medical and psychosocial ailments associated with alcoholism is important. Posttransplant monitoring for cardiovascular disease and withdrawal syndromes is required in the early postoperative setting, whereas monitoring for recidivism and malignancy are late postoperative issues.

Original languageEnglish (US)
Pages (from-to)249-255
Number of pages7
JournalSeminars in liver disease
Volume24
Issue number3
DOIs
StatePublished - Aug 1 2004

Fingerprint

Alcoholics
Transplantation
Alcoholic Liver Diseases
Liver Transplantation
Liver Diseases
Transplants
Graft Survival
Alcoholism
Cardiovascular Diseases
Alcohols
Morbidity
Survival
Neoplasms

Keywords

  • Alcohol
  • Liver disease
  • Transplantation

ASJC Scopus subject areas

  • Hepatology

Cite this

Transplantation in the alcoholic patient. / Watt, Kymberly D S; McCashland, Timothy M.

In: Seminars in liver disease, Vol. 24, No. 3, 01.08.2004, p. 249-255.

Research output: Contribution to journalReview article

Watt, Kymberly D S ; McCashland, Timothy M. / Transplantation in the alcoholic patient. In: Seminars in liver disease. 2004 ; Vol. 24, No. 3. pp. 249-255.
@article{3f98c43eec0e466798a68af0188806da,
title = "Transplantation in the alcoholic patient",
abstract = "Alcoholic liver disease (ALD) is the second leading indication for transplantation in the United States. Most transplant programs in the United States require a minimum of 6 month's abstinence before transplantation is performed. Most studies have shown a recidivism rate of between 20 and 30{\%} by 2 years after orthotopic liver transplantation (OLT). Higher rates of recidivism are reported if pre-OLT abstinence was < 6 months. The impact of recidivism on patient and graft survival is not clear because most reports include patients who consume alcohol in small amounts or infrequently. Equal post-OLT survival for ALD patients and non-ALD patients has been demonstrated, and ALD patients are not thought to suffer greater morbidity post transplant than non-ALD patients. Careful pretransplant assessment for concomitant medical and psychosocial ailments associated with alcoholism is important. Posttransplant monitoring for cardiovascular disease and withdrawal syndromes is required in the early postoperative setting, whereas monitoring for recidivism and malignancy are late postoperative issues.",
keywords = "Alcohol, Liver disease, Transplantation",
author = "Watt, {Kymberly D S} and McCashland, {Timothy M}",
year = "2004",
month = "8",
day = "1",
doi = "10.1055/s-2004-832938",
language = "English (US)",
volume = "24",
pages = "249--255",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "3",

}

TY - JOUR

T1 - Transplantation in the alcoholic patient

AU - Watt, Kymberly D S

AU - McCashland, Timothy M

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Alcoholic liver disease (ALD) is the second leading indication for transplantation in the United States. Most transplant programs in the United States require a minimum of 6 month's abstinence before transplantation is performed. Most studies have shown a recidivism rate of between 20 and 30% by 2 years after orthotopic liver transplantation (OLT). Higher rates of recidivism are reported if pre-OLT abstinence was < 6 months. The impact of recidivism on patient and graft survival is not clear because most reports include patients who consume alcohol in small amounts or infrequently. Equal post-OLT survival for ALD patients and non-ALD patients has been demonstrated, and ALD patients are not thought to suffer greater morbidity post transplant than non-ALD patients. Careful pretransplant assessment for concomitant medical and psychosocial ailments associated with alcoholism is important. Posttransplant monitoring for cardiovascular disease and withdrawal syndromes is required in the early postoperative setting, whereas monitoring for recidivism and malignancy are late postoperative issues.

AB - Alcoholic liver disease (ALD) is the second leading indication for transplantation in the United States. Most transplant programs in the United States require a minimum of 6 month's abstinence before transplantation is performed. Most studies have shown a recidivism rate of between 20 and 30% by 2 years after orthotopic liver transplantation (OLT). Higher rates of recidivism are reported if pre-OLT abstinence was < 6 months. The impact of recidivism on patient and graft survival is not clear because most reports include patients who consume alcohol in small amounts or infrequently. Equal post-OLT survival for ALD patients and non-ALD patients has been demonstrated, and ALD patients are not thought to suffer greater morbidity post transplant than non-ALD patients. Careful pretransplant assessment for concomitant medical and psychosocial ailments associated with alcoholism is important. Posttransplant monitoring for cardiovascular disease and withdrawal syndromes is required in the early postoperative setting, whereas monitoring for recidivism and malignancy are late postoperative issues.

KW - Alcohol

KW - Liver disease

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=4444264039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444264039&partnerID=8YFLogxK

U2 - 10.1055/s-2004-832938

DO - 10.1055/s-2004-832938

M3 - Review article

C2 - 15349803

AN - SCOPUS:4444264039

VL - 24

SP - 249

EP - 255

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 3

ER -